Sunshine Biopharma (SBFM) Capital Expenditures (2015 - 2026)

Sunshine Biopharma has reported Capital Expenditures for 11 years, with the latest figure at $5129.0 in Q1 2026.

• For the quarter ending Q1 2026, Capital Expenditures fell 31.52% year-over-year to $5129.0; the trailing twelve-month figure through Mar 2026 stood at $172130.0 (down 89.25% YoY), and the FY2025 full-year result was $174491.0, down 89.47% from the prior year.
• Capital Expenditures for Q1 2026 stood at $5129.0, up from -$1039.0 in the prior quarter.
• The five-year high for Capital Expenditures was $974513.0 in Q2 2024, with the low at -$382363.0 in Q4 2023.
• Historically, Capital Expenditures has averaged $138160.7 across 5 years, with a median of $36285.5 in 2023.
• Annual changes were most pronounced in 2023 — Capital Expenditures slumped 297.11% — and 2024, when it soared 5266.46%.
• Sunshine Biopharma's Capital Expenditures stood at $193982.0 in 2022, then tumbled by 297.11% to -$382363.0 in 2023, then jumped by 126.83% to $102600.0 in 2024, then tumbled by 101.01% to -$1039.0 in 2025, then jumped by 593.65% to $5129.0 in 2026.
• The last three Capital Expenditures figures came in at $5129.0 (Q1 2026), -$1039.0 (Q4 2025), and $8040.0 (Q3 2025), per Business Quant data.